GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UCB SA (WBO:UCB) » Definitions » Interest and Commission Paid

UCB (WBO:UCB) Interest and Commission Paid


View and export this data going back to 2018. Start your Free Trial

What is UCB Interest and Commission Paid?

Interest and Commission Paid only applicable to companies reporting Cash Flow from Operations in direct method.


UCB (WBO:UCB) Business Description

Industry
Address
Allee de la Recherche, 60, Brussels, BEL, B-1070
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), and Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome).